Download Free Sample
Buy Now
Market Outlook
The global photodynamic therapy market, valued at USD 672 million in 2025, is projected to reach USD 749 million in 2026 and USD 1,532 million by 2035, representing a CAGR of 8.3% during the forecast period 2026 to 2035.
See What’s in the Full Report - Request Your Complimentary Insights!
Market Report: Key Takeaways
Market Size & Trends
- In terms of target indication, actinic keratosis holds the highest share (over 35%) of the market.
- With respect to therapeutic areas, oncological disorders dominate the current market.
- In terms of key geographical regions, Europe holds the highest share (nearly 50%) of the market.
Key Market Statistics
- Market Size in 2026: $749 Million
- Estimated Market Size in 2035: $1,532 Million
- CAGR (2026-2035): 8.3%
- Europe: Largest market in 2026
- North America: Fastest growing region
Market Introduction
Light activated therapy / photodynamic therapy (PDT) is a targeted, minimally invasive treatment modality. It utilizes photosensitizing agents activated by specific light wavelengths to produce cytotoxic reactive oxygen species, enabling selective destruction of cancer cells and pathological tissues. Notably, the concept of light activated therapy / photodynamic therapy originated in the early 20th century and has been refined through decades of clinical research. It is worth mentioning that PDT has evolved into a versatile treatment option for oncological disorders, offering advantages such as reduced systemic toxicity compared to traditional chemotherapy and radiotherapy. Further, advancements in photosensitizer design, such as porphyrin-based conjugates and nanoparticle formulations combined with precision light-delivery devices, have expanded PDT's role beyond cancer treatment to antimicrobial applications.
In photodynamic therapy, photosensitizers are administered locally at tumor sites, minimizing systemic exposure and reducing complications such as prolonged skin photosensitivity and off-target effects. Further, this approach has also shown positive outcomes in treating skin conditions such as actinic keratosis, acne, warts and microvesicles, making it ideal for the treatment of broad range of skin conditions.
Given the various benefits of light activated therapies, several industrial stakeholders have undertaken various initiatives to develop effective photoimmunotherapies / photodynamic therapies against multiple target indications. It is important to highlight here that over 70 therapies are currently under clinical development and multiple photodynamic therapies have already received approval. Moreover, several key players are focusing on leveraging nanotechnology such as quantum dots as advanced photosensitizers to treat skin cancer. Owing to the ongoing advancements and rising research on these therapies, the photodynamic therapy market is likely to witness significant market growth during the forecast period.
Market Segmentation
Based on the research, we have segmented the Photodynamic Therapy Market Report into target indication, therapeutic area and key geographical regions.
By Target Indication
- Actinic Keratosis
- Prostate Cancer
- Age-related Macular Degeneration
- Head and Neck Squamous Cell Carcinoma
- Basal Cell Carcinoma
- Port Wine Stain
- Barrett’s Esophagus
- Esophageal Cancer
- Endobronchial Cancer
- Lung Cancer
- Bowen’s Disease
- Brain Cancer
- Bladder Cancer
- T-cell Lymphoma
- Urothelial Cancer
By Therapeutic Area
- Oncological Disorders
- Dermatological Disorders
- Ophthalmic Disorders
By Key Geographical Regions
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Middle East and North Africa
- Israel
Want Information on Specific Region / Segment?
Photodynamic Therapy Market Key Insights
What are the Latest Photodynamic Therapy Market Trends?
- Rising Incidence of Cancer: With the growing incidence of skin cancer globally, there is an increase in demand for effective and minimal invasive treatment such as light activated therapies. According to American Cancer Society, there were 104,960 new cases of skin cancer reported in 2025 in the US alone, with high recurrence rates. For instance, basal cell carcinoma has shown a recurrence rate of 10% and some rare skin cancers have recurrence rate of 40%.
Notably, light activated therapy addresses this challenge by utilizing topical photosensitizers that selectively eradicate precancerous actinic keratosis and early non-melanoma skin cancers (NMSCs), thereby driving growing demand for these therapies in skin cancer treatment. In addition, researchers are also exploring the use of light-activated therapy in other hard-to-treat cancers, including advanced stomach cancer. They have developed an innovative light-activated immunotherapy, that uses specially engineered proteins called betabodies, which are injected into the abdomen and selectively bind to cancer cells while sparing healthy tissue.
- Increase in Clinical Trial Activity: Clinical trial activity in the photodynamic therapy market has seen a significant increase, driven by advancements in photosensitizers, light delivery systems, and combination therapies targeting oncological and dermatological disorders. Notably, majority of the registered trials are focused on solid tumors such as glioblastoma, esophageal cancer, and non-melanoma skin cancers, while expanding into antimicrobial PDT applications for infectious diseases.
Your Business is Unique – Why Shouldn’t Your Report Be?
What are the Key Drivers for Market Growth?
The photodynamic therapy market growth is driven by various factors, including the rising global incidence of cancer and dermatological disorders, which drives demand for targeted, minimally invasive treatments that leverage photosensitizers and light activation for precise tumor ablation with fewer systemic toxicities. Further, advancements in photosensitizer formulations and light delivery devices, such as improved diode laser and fiber optics enhance therapeutic efficacy through deeper tissue penetration for better oncology outcomes. Moreover, increasing regulatory approvals for PDT in antimicrobial applications and age-related macular degeneration (AMD), alongside supportive reimbursement policies have also accelerated clinical adoption of light activated therapies. Notably, photobiomodulation, a form of light therapy that utilizes non-ionizing forms of light sources including lasers, LEDs, and broadband light is the first non-invasive treatment authorized by the US Food and Drug Administration (USFDA) for use in treating dry AMD
Pay Only for What You Need – The Best Way to Optimize
Recent Developments in Photodynamic Therapy Market
- In January 2026, Ferring Pharmaceuticals entered into a clinical development agreement with Theralase Technologies. The agreement builds on Theralase’s existing clinical program with a new cohort investigating its investigational light-activated small molecule Ruvidar (TLD-1433) in combination with Ferring’s intravesical non-replicating gene therapy ADSTILADRIN.
- In June 2025, Biofrontera entered into a strategic partnership in order to acquire all the US assets associated with Ameluz and RhodoLED, including New Drug Application (NDA) and associated patents from Germany-based Biofrontera.
- In May 2025, Sun Pharmaceutical announced that the USFDA has granted premarket approval application (PMA) approval to its next generation of BLU-U Blue Light Photodynamic Therapy Illuminator. The new model (LED BLU-U) in combination with LEVULAN KERASTICK (aminolevulinic acid HCl) is recommended for the treatment of actinic keratoses.
- In June 2025, physicians at the LV Prasad Eye Institute evaluated a new photodynamic therapy, PDAT-RB, for treating a rare eye infection called acanthamoeba keratasis. This therapy uses a dye called rose Bengal, which is activated by light to produce powerful molecules that effectively combat the pathogen.
Market Share Insights
Will Oncological Disorder Segment Hold the Highest Share in the Future?
- In 2026, the oncological disorders segment occupies the highest photodynamic therapy market share (close to 50%) and is likely to grow at a higher CAGR (11%) during the forecast period.
- This is driven by the rising global incidence of cancer, especially skin, lung, esophageal, and head-and-neck cancer, which has fueled the demand for PDT due to its targeted mechanism of selectively destroying malignant cells through light-activated photosensitizers.
Which Target Indication Accounts for the Largest Photodynamic Therapy Market Share?
- In 2026, the actinic keratosis segment occupies higher market light activated therapy size (with over 35% share). This dominance is due to the rising prevalence of actinic keratosis, a precancerous skin condition linked to chronic UV exposure, along with PDT’s enhanced cosmetic outcomes compared to cryotherapy.
- It is worth highlighting that the market share for head and neck squamous cell carcinoma is likely to grow at a relatively higher CAGR, during the forecast period. This is likely due to its rising global incidence, along with clinical advancements such as PDT combinations with immunotherapies, which show promising response rates and reduced severe toxicities.
Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed
Regional Analysis: Which Regions are Showing the Fastest Growth in Light Activated Therapy Industry?
Europe: Dominating the Market by Securing Highest Share
According to our photodynamic therapy market forecast, Europe is likely to capture the highest share (nearly 50%) in 2026. Europe's dominance is due to the high prevalence of non-melanoma skin cancers like actinic keratosis and basal cell carcinoma, which affect 20% of citizens annually, driving demand for PDT. Further, robust healthcare systems in Germany, France, and the UK support widespread outpatient PDT adoption, bolstered by national guidelines, reimbursement policies and ongoing trials for oncological and dermatological indications.
North America: An Emerging Growth Spot
The market in North America is likely to grow at the highest CAGR (14%), during the forecast period till 2035, as per our photodynamic therapy market analysis. This growth is due to the rapid digital transformation, expanding pharmaceutical R&D investments, and strong government initiatives to modernize healthcare infrastructure in this region.
Scope of Photodynamic Therapy Market Report
| Key Report Attribute | Details | |
| Historical Trend | Since 2021 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | $ 746 Million | |
| Market Size 2035 | $ 1,532 Million | |
| CAGR (Till 2035) | 8.3% | |
| Segments Covered |
|
|
| Key Players Profiled |
(A complete list of companies captured is available in the report) |
|
| PowerPoint Presentation (Complimentary) | Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) | Available | |
